Business Wire

4Moving Biotech announces successful results from its Lasare Phase I 4P004 Clinical Trial intraarticular Liraglutide for knee osteoarthritis patients

Share

4Moving Biotech, a spin-off of 4P-Pharma committed to developing first-in-class treatments to modify the natural course of knee osteoarthritis, announces the successful achievement of the Phase 1 Lasare trial in knee osteoarthritis (OA) patients using 4P004.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240609275171/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

Lasare Phase I trial is a multi-center, randomized, double-blinded, placebo-controlled involving 34 patients across three sites in Belgium.

The study evaluated the safety, tolerability, and pharmacokinetics of ascending doses of a single intra-articular injection of liraglutide (4P004).

The trial reached its primary objective, confirming that intraarticular liraglutide (4P004) was safe and well tolerated. A pharmacological active dose has been identified, with similar expected adverse events (EAEs) in the 4P004 groups as the placebo group. Pharmacokinetics, both observed and simulated Cmax values, also indicated lower systemic exposure than reported for subcutaneous liraglutide injection from the approved product, Victoza®, affirming the company’s plan to pursue a 505(b)(2) regulatory pathway in the US for 4P004.

Pr. Francis Berenbaum, Co-founder and Chief Medical Officer of 4Moving Biotech, declared: "The Success of the Phase 1 study of 4P004 underscores the quality of our advancements in the quest for therapeutic solutions for patients suffering from knee osteoarthritis. Furthermore, with the established safety and tolerability profiles, we are progressing confidently to the next stage of clinical development with 4P004."

As for ultimate goal, 4Moving Biotech’s strategy intends to secure accelerated approvals in the US and EU for early market entry at the end of the planned Phase 2b efficacy and safety trial. Toward this goal, the company recently received constructive pre-IND guidance from the FDA, translating 4Moving Biotech’s planned potential accelerated approval driven strategy into a highly differentiated clinical program catalyzed by a unique combination of reasonably likely surrogate endpoints, supported by sophisticated in silico AI-based prognostic modelling.

Revital Rattenbach, Chairwoman of 4Moving Biotech, stated: "Beyond the positive results from our phase I clinical study on knee osteoarthritis, the FDA's positive echoing has built a tremendous momentum for our accelerated strategy to the market, with hopes to bring to OA patients the first therapy being able to modify the natural course of the disease."

About 4Moving Biotech
Incorporated in mid 2020 as a spin-off of 4P-Pharma, 4Moving Biotech is a clinical stage biotechnology company dedicated to the development of the Disease-Modifying Osteoarthritis Drug (DMOAD). Its mission is to provide a sustainable therapeutic solution to the significant unmet medical need of osteoarthritis. The company is headquartered at the Pasteur Institute in Lille, France. 
Website: https://www.4movingbiotech.com/
LinkedIn: https://fr.linkedin.com/company/4moving-biotech

About Lasare
This project has received funding from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and innovation program. The funding agencies supporting this work are (in alphabetical order of participating countries): France: BPI France ; Germany: Project Management Agency (DLR), which acts on behalf of the Federal Ministry of Education and Research (BMBF); The Netherlands: Netherlands Enterprise Agency (RVO); Switzerland: Innosuisse (the Swiss Innovation Agency).

The only version of the 4Moving Biotech press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press :
Emmanuel Dadje
Communication Manager
+33 6 30 06 12 13 
emmanuel.dadje@4P-Pharma.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

euNetworks refinances part of its existing debt and secures additional sustainability-linked debt funding commitment to drive continued growth19.6.2024 14:57:00 CEST | Press release

euNetworks Holdings Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced that it has completed the refinancing of existing debt as well as raising significant undrawn, committed debt facilities. This will fund the construction and development of the next generation of critical bandwidth infrastructure in Europe. The new long-term infrastructure financing solution provides total debt facilities of €1,260 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240619905010/en/ Katherine Alexakis, Chief Financial Officer, euNetworks (Photo: Business Wire) euNetworks builds and invests in city and long haul fibre networks to connect key European data centres and data hubs. The company owns and operates deep fibre networks in 18 cities as well as a highly differentiated long haul network that spans 45,000 route kilometres across 17 countries. As a specialist in the sector, euNetworks contin

Scientist.com Unveils Elisa: An LLM-Powered Research Assistant for Scientists in the Pharmaceutical and Biotechnology Industries19.6.2024 13:55:00 CEST | Press release

Scientist.com, the world’s leading marketplace for biopharma research, today announced the launch of a new large language model (LLM)-powered research assistant called Elisa, named in homage to a widely used research assay and to ELIZA, an early 1960s chatbot. Elisa is the newest addition to a suite of proprietary AI-powered apps created by Scientist.com to improve and accelerate drug research. Marketplace users can now benefit from a powerful, scalable, and intuitive LLM assistant that understands the nuances of pharmaceutical research and has been trained on Scientist.com’s public data sources. “Elisa is a bridge between advanced technology and our customers, providing them with instant access to marketplace information and a conversational interface that understands their research needs,” said Chris Petersen, Founder and CTO of Scientist.com. “It’s the latest in a series of LLM-powered tools we’ve built to help life science researchers run their drug discovery programs faster and at

SES Announces Successful Syndication and Raising of €3 Billion Acquisition Financing19.6.2024 11:59:00 CEST | Press release

SES S.A. announces the successful syndication of a €3 billion equivalent acquisition financing package to support the earlier announced agreement for SES to acquire Intelsat S.A.. Prior to the Intelsat deal announcement, Deutsche Bank AG and Morgan Stanley jointly had underwritten a €3 billion bridge facility to support SES’s financing requirements as part of the agreement to acquire Intelsat. This €3 billion bridge facility has been successfully syndicated now, with a highly oversubscribed level of commitments, to an international group of existing relationship and new banks in the form of a €2.1 billion bridge facility and US$1 billion term loan. The term loan was upsized in syndication on the back of a strong response from the bank group. The bridge facility serves to provide financing certainty and flexibility in the issuance of bonds. The bridge facility has tenor of 12 months and is extendable twice by a further six months while the term loan has a five-year amortising tenor from

Tecnotree Announces Strategic Partnership with HCLTech to Bring Advanced 5G-Led GenAI Solutions for Global Telcos19.6.2024 11:42:00 CEST | Press release

Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced a strategic partnership with HCLTech, a leading global technology company, to co-develop advanced 5G-led generative AI (GenAI) solutions for the telecom industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240619554988/en/ Tecnotree Announces Strategic Partnership with HCLTech to Bring Advanced 5G-Led GenAI Solutions for Global Telcos (Graphic: Business Wire) This partnership combines Tecnotree’s proven 5G and AI-led BSS platform capabilities and HCLTech’s deep expertise in driving digital transformation for telcos and CSPs. Together, the companies will deliver solutions designed to redefine digital experiences through the integration of Digital BSS and Tecnotree Sensa AIML fabric, leading to comprehensive business transformation. The solutions will enable customers to enhance business agility and faster re

LatticeFlow AI Announces Key Innovation to Accelerate Development of Deepfake Detection Software in Advance of U.S. Elections19.6.2024 10:34:00 CEST | Press release

LatticeFlow AI, the leading platform for building trustworthy AI applications, announces LatticeFlow AI Audio, the first product designed to find and identify model errors in audio AI applications. This release addresses the pressing demand for reliable voice deepfake detection solutions in advance of the 2024 U.S. elections. In this context, LatticeFlow AI Audio, combined with the company’s existing capabilities in computer vision, makes it the most advanced solution for deepfake detectors to combat deepfake threats combining audio and video. “We believe that there is no place for deepfakes in civil, ethical societies,” said Dr. Petar Tsankov, Co-founder and CEO at LatticeFlow AI. “Ethical, safe, and trustworthy AI are the foundational values of our company – and why we want to help address deepfakes detection in advance of the 2024 elections. LatticeFlow AI Audio is the industry’s only product that can automatically find and identify AI audio data and model errors, enabling our clien

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye